Opendata, web and dolomites

TKI resistance SIGNED

Resistance mechanisms to tyrosine kinase inhibitors in solid tumors

Total Cost €


EC-Contrib. €






 TKI resistance project word cloud

Explore the words cloud of the TKI resistance project. It provides you a very rough idea of what is the project "TKI resistance" about.

persistor    elucidate    ultimately    probably    oncogene    kinase    biopsies    tyrosine    addicted    populations    stage    cancer    adaptive    systematic    laboratory    arsenal    develops    over    combinatorial    sensitizers    groups    tolerant    designs    molecular    escape    standardized    addiction    therapeutic    overcome    successfully    few    discovery    screens    innovative    inhibitors    tki    acquired    tolerate    drug    lines    tkis    validate    expanded    scrutinize    reprogrammation    screen    worldwide    establishing    understand    modifiers    whereby    mechanisms    chemotherapeutic    translational    performed    strategy    limited    strategies    patients    inhibitor    persistors    apoptosis    cellular    epigenetic    alternative    cells    screening    vitro    driver    therapies    requisite    xenografts    absolute    single    models    extremely    resistant    emergence    agents    rational    additionally    patient    subsequent    guidance    cell    interfere    involve    resistance    acquisition    treatments   

Project "TKI resistance" data sheet

The following table provides information about the project.


Organization address
address: Rue Camille Desmoulins 39
postcode: 94805

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2021-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) coordinator 1˙500˙000.00


 Project objective

Over the past 10 years, the chemotherapeutic arsenal has been expanded to include molecular-targeted therapies based on the principle that cancer cells become addicted to a single driver oncogene. However, use of these new therapies is limited due to development of acquired resistance. To fully understand how resistance develops, patient-derived models are an absolute pre-requisite, but establishing them remains extremely challenging. Few groups worldwide have successfully implemented a systematic standardized approach to facilitate translational cancer research discovery. My project aims to provide rational therapeutic guidance for combinatorial or adaptive designs to overcome acquired resistance to tyrosine kinase inhibitors (TKIs) in patients with oncogene-addiction. By establishing new laboratory models of resistance directly from patient biopsies (patient derived cell lines and xenografts) I will elucidate the molecular mechanisms whereby cancer cells escape targeted treatments. I will then implement innovative approaches to overcome resistance using TKI combinatorial screens, apoptosis sensitizers and by screening for epigenetic modifiers. Additionally, I will scrutinize the emergence of resistance acquisition in vitro. Current working models involve “persistor” cellular populations able to tolerate the TKI and, in a subsequent step, to become fully resistant to the drug. This drug tolerant persistor stage most probably involves epigenetic reprogrammation. An epigenetic inhibitor screen will be performed to identify agents able to interfere with the emergence of persistors and ultimately with the acquisition of TKI resistance. These results should provide an alternative strategy to validate innovative combinatorial drug strategies to avoid emergence of resistance in patients.


year authors and title journal last update
List of publications.
2019 Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z Rizvi, Rosa L Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hol
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
published pages: clincanres.1104., ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-19-1104
Clinical Cancer Research 2019-10-10
2019 Francesco Facchinetti, Antoine Hollebecque, Rastilav Bahleda, Yohann Loriot, Ken A Olaussen, Christophe Massard, Luc Friboulet
Facts and new hopes on selective FGFR inhibitors in solid tumors
published pages: clincanres.2035., ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-19-2035
Clinical Cancer Research 2019-10-10
2018 Gonzalo Recondo, Francesco Facchinetti, Ken A. Olaussen, Benjamin Besse, Luc Friboulet
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
published pages: , ISSN: 1759-4774, DOI: 10.1038/s41571-018-0081-4
Nature Reviews Clinical Oncology 2019-09-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TKI RESISTANCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TKI RESISTANCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

DINAMIX (2019)

Real-time diffusion NMR analysis of mixtures

Read More  

MEMO (2020)

The Memory of Solitons

Read More  

CONTROL (2019)

Laser control over crystal nucleation

Read More